BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 16195804)

  • 1. Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches.
    Rood BR; MacDonald TJ
    J Neurooncol; 2005 Dec; 75(3):267-72. PubMed ID: 16195804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating molecular tools into clinical trials and treatment for gliomas?
    Lassman AB; Holland EC
    Curr Opin Neurol; 2007 Dec; 20(6):708-11. PubMed ID: 17992094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment strategies for malignant gliomas.
    Sathornsumetee S; Rich JN
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exposing the defenses of gliomas.
    Heimer H
    J Natl Cancer Inst; 1997 Nov; 89(22):1662. PubMed ID: 9390533
    [No Abstract]   [Full Text] [Related]  

  • 5. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology.
    Brandes AA; Franceschi E
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1129-31. PubMed ID: 16925479
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of novel targeted therapies in the treatment of malignant glioma.
    Rich JN; Bigner DD
    Nat Rev Drug Discov; 2004 May; 3(5):430-46. PubMed ID: 15136790
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutations in chromatin machinery and pediatric high-grade glioma.
    Lulla RR; Saratsis AM; Hashizume R
    Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
    Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
    Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.
    Gilheeney SW; Kieran MW
    Future Oncol; 2012 May; 8(5):549-58. PubMed ID: 22646770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENU administration causes genomic instability along with single nucleotide polymorphisms in p53 during gliomagenesis: T11TS administration demonstrated in vivo apoptosis of these genetically altered tumor cells.
    Mukherjee J; Ghosh A; Ghosh A; Chaudhuri S
    Cancer Biol Ther; 2006 Feb; 5(2):156-64. PubMed ID: 16357521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigational new drugs for brain cancer.
    Staedtke V; Bai RY; Laterra J
    Expert Opin Investig Drugs; 2016 Aug; 25(8):937-56. PubMed ID: 27170161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
    Blumenthal DT; Dvir A; Lossos A; Tzuk-Shina T; Lior T; Limon D; Yust-Katz S; Lokiec A; Ram Z; Ross JS; Ali SM; Yair R; Soussan-Gutman L; Bokstein F
    J Neurooncol; 2016 Oct; 130(1):211-219. PubMed ID: 27531351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.
    Juratli TA; Qin N; Cahill DP; Filbin MG
    Pharmacol Ther; 2018 Feb; 182():70-79. PubMed ID: 28830841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities.
    Haase S; Nuñez FM; Gauss JC; Thompson S; Brumley E; Lowenstein P; Castro MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular diagnostics as a tool to personalize treatment in adult glioma patients.
    Jeuken JW; van der Maazen RW; Wesseling P
    Technol Cancer Res Treat; 2006 Jun; 5(3):215-29. PubMed ID: 16700618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.
    Fernández MB; Alonso VP
    Childs Nerv Syst; 2016 Oct; 32(10):1939-45. PubMed ID: 27659836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers and targeted therapy in pediatric low-grade glioma.
    de Blank P; Fouladi M; Huse JT
    J Neurooncol; 2020 Oct; 150(1):5-15. PubMed ID: 32399739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms and therapeutic targets in pediatric brain tumors.
    Liu KW; Pajtler KW; Worst BC; Pfister SM; Wechsler-Reya RJ
    Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.
    Bredel M; Pollack IF; Hamilton RL; James CD
    Clin Cancer Res; 1999 Jul; 5(7):1786-92. PubMed ID: 10430083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.